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Summary
Cyclosporin A (CSA), FK506, and glucocorticosteroids all inhibit the production of lymphokines
by decreasing lymphokine gene expression. Previous experiments have defined six different sites
that may contribute to the transcriptional control of the interleukin 2 (IL2) promoter, and for
each, active nuclear binding factors are induced upon mitogenic stimulation. While dexamethasone
markedly blocks the increase in IL2 mRNA in stimulated human blood T cells, we found that
the drug does not block the appearance of factors that bind to the transcriptional control sites
termed AP-1, AP-3, NF-kB, OCT1, B site, and NF-AT. In contrast, both CSA and FK506 have
similar effects: the drugs cause modest decreases in AP-3 and NF-kB, and marked decreases in
the activity of AP-1 and NF-AT Therefore, CSA and FK506, while chemically different, seem
to act upon a similar pathway that leads to IL2 gene expression, whereas glucocorticoids do
not affect this pathway.
variety of immunosuppressants block T cell prolifera A tion and lymphokine production. A major site of ac-
tion of these immunosuppressive drugs is at the level of lym
phokine gene expression. This was notedfirst for cyclosporin
A (CSA) (1-4), which acts primarily at the level of lym-
phokines rather than other components of T cell activation,
such as the p55 IL2R and cfos (2). Two other drugs, dexa-
methasone and FK506, also act primarily at the levelof 11,2
gene expression (5-7). It is likely that glucocorticoids have
a different mechanism of action than CSA and FK506, since
steroids affect many cell types, whereas CSA and FK506 are
more T cell restricted.
To gain more insight into the mechanism ofaction of im-
munosuppressive drugs, we have taken advantage of recent
progress in defining nuclear factors that bind to the IL2 pro-
moter. An activation-dependent enhancer within sequences
-326 to -52 of the 5' flanking region of the IL2 gene has
been identified (for review see reference 8). In this enhancer
reside several elements common to other genes, like the NFkB,
AP-1, AP-3, and OCT-1 sites, as well as a site that seems re-
stricted to activated lymphoid cells and is called the nuclear
factor for activated T cells (NF-AT) (9). Here, we report the
induction of these nuclear factors in primary populations of
human blood T cells. We show that FK-506 and CSA
markedly inhibit the activation of factors that bind to the
AP-1 and NF-AT sites, whereas dexamethasone has no effect
on all six nuclear binding factors tested.
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Materials and Methods
Cell Cultures.
￿
Briefly, human mononuclear cells were isolated from
huffy coats on Ficoll-Hypaque density gradients, washed in PBS,
and rosetted with neuraminidase-treated sheep erythrocytes. The
rosette-positive fraction was further purified by passage over a nylon
wool column and used as a source of T cells. T cells were cultured
at 5 x 106/ml in RPMI 1640 supplemented with 10% heat-
inactivated FCS, 20,ug/ml gentamicin sulfate, and 5 x 10-5 M
2-ME. Cells were stimulatedwith PHA (Gibco Laboratories, Grand
Island, NY) at 1 Rg/ml and PMA (Sigma Chemical Co., St. Louis,
MO) at 5 ng/mlin the presence or absence ofCSA or CSH (Sandoz,
Basel, Switzerland) at 1 hg/ml; FK506 (Fujisawa Pharmaceutical
Co. Ltd., Osaka, Japan) at 100 ng/ml; or dexamethasone (Sigma
Chemical Co.) at 10-7 M.
Nuclear Extracts.
￿
These were prepared from 2-4 x 108 T cells
by homogenization in two-cell pellet volumes of 10 mM Hepes,
pH 7.9, 10 mM KCI, 1.5 mM MgCIZ, 1 mM EDTA, 0.5 mM
DTT, 0.5 mM PMSF, and 10% glycerol (10). Nuclei were cen-
trifuged at 1,000 g for 5 min, washed, and resuspended in two
volumes of the above solution. 3 M KCI was added drop by drop
to reach 0.39 M KCI. Nuclei were extracted at 4°C for 1 h and
centrifuged at 100,000 g for 30 min. The supernatants were dia-
lyzed in 20 mM Hepes, pH 7.9, 50 mM KCI, 20% glycerol, 0.5
mM PMSF, and 1 mM EDTA, and"then clarified by centrifugation
and stored at -80°C. Protein concentration was determined using
the Bradford method.
DNA-Protein Binding Assay.
￿
0.2 ng (-10' cpm) ofend-labeled
DNA fragments were incubated at room temperature for 20 min
with 5-10 jug of nuclear protein in the presence of 2 pg Poly(dl-
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Volume 172 December 1990 1869-1872dC) in 20 jl of 10 mM Tris HCI, pH 7.5, 50 mM NaCl, 1 mM
EDTA, 1mM DTT, and 5% glycerol (this buffer wasused forNF-
kB, NF-AT, and B sites) . For AP-1, AP-3, and OCT-1 sites, the
buffer was 20 mM Hepes, pH 7.9, 4% Ficoll, 2.5 MM MgCIZ,
1mM DTT, and 40mM KC1 . Protein-DNAcomplexes were sepa-
rated from free probe on a 4% polyacrylamide gel in 0.25x TBE
at 150V for 1.5 h at room temperature . The gels were dried and
exposed to X-ray film . For each site,we verified that a 20-fold molar
excess of specific cold oligonucleotide would compete the binding
of proteins to a radiolabeled probe, whereas a similar excess from
another site would not.
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Figure 1.
￿
Effects of CSA on the
induction of nuclear factors that
bind to elements of the 11,2 en-
hancer. Human bloodT cells were
left unstimulated (Unst) or were
stimulated withPHA (1 gg/ml) and
PMA (5 ng/ml) (PIP) in the pres-
ence or absence of CSA or the
nonimmunosuppressive analogue
CSH (1 Ftg/ml) . After 5 h, the cells
were collected and nuclear extracts
prepared . 10 Rg of nuclear proteins
were incubated with 0.2 ng of the
indicated 32P end-labeled oligonu-
cleotides. Protein-DNA complexes
(arrows) were separated from free oli-
gonucleotide (lower part of each
lane) in low ionic strength4% poly-
acrylamide gels .
DNA Probes .
￿
Oligonucleotides were synthesized by The Rock-
efeller University Facility with aDNA synthesizer (Applied Bio-
systems, Inc., Foster City, CA). The following probes were used :
the NF-AT binding site, -254 to -285 of the IL-2 promoter,
5'-GGAGGAAAAACTGTTTCATACAGAAGGCGT3' (9) ; the
NF-kB binding site, -206 to -195 region of the 11,2 promoter,
5'-GGGATTTCACCT3' (11); theOCT -1 binding site, 5'-ACT
CTTCACCTTATTTGCATAAGCGATTCTA 3', used for the pur-
ification of the OTF-1 transcription factor and kindly provided by
Dr. N . Heintz (The Rockefeller University) ; theAP-1 binding site,
-157 to -140 of the IL2 promoter, 5'-TTCCAAAGAGTCAT
Figure 2.
￿
Effects ofFK506 on the
induction of nuclear factors that
bind to elements of the 11,2 en-
hancer. The experiments were the
same as those in Fig . 1, except that
FK506 (100 ng/ml) was used as the
immunosuppressant, and nuclear
extracts from Hela cells were also
tested . Arrows indicate the specific
DNA-protein complexes.Figure 3 .
￿
Effects of CSA on the induction ofnuclear factors in response
to mitogenic anti-T cell mAb. The experiments were the same as those
in Fig. 1, except that an anti-CD28 mAb, 9.3 (ascites, kindly provided
by Dr. P . Martin, Seattle, WA, and used at 1:1,000), was used instead
ofPHA as the mitogen.
CAG3' (11) ; the AP-3binding site used for the purification ofAP-3,
5'-TGTGGAAAGTCCCA-3' (12) ; and theB site, -82 to -67of
the 11,2 promoter, 5'-TAATATGTAAAACATT3' (13) . Probes were
labeled with [32p]ATP .
Results and Discussion
DNA-nuclear protein interactions were monitored with
standard electrophoretic mobility shift assays (EMSA) . Ex-
tracts of nuclei from mitogen stimulated T cells were pre-
pared 5 h after application of the mitogen in the presence
or absence of an immunosuppressive drug. Resting T cells
did not contain active factors that bind to the NF-AT, NF-
kB, AP-1, AP-3, andB sites, but these activities were induced
by stimulation with PHA andPMA (Fig. 1) . The immunosup-
pressive CSA, but not the nonimmunosuppressive analogue
CSH, markedly inhibited the induction ofNF-AT and AP-1,
but only partially blocked induction ofNF-kB and AP-3 (Fig.
1) . Inhibition by CSA ofNF-AT was also observed in stimu-
lated Jurkat cells (14) . The fact that CSA primarily acts on
NF-AT and AP-1 is of interest . Both are distinct from other
transcription factors in requiringnew protein synthesis as well
as two signals, in this case lectin plus PMA (Granelli-Piperno,
A ., manuscript submitted for publication) .
Figure 4.
￿
Effects ofdexamethasone on the induction ofnuclear factors
that bind to elements of the IL2 enhancer. The experiments were the same
as those in Fig . 1, except that dexamethasone (10 -7 M) was used as the
immunosuppressive . Arrows indicate the specific DNA-protein complexes .
We next examined the effect of another immunosuppres-
sive drug, FK506 . FK506, like CSA, inhibits T cell prolifer-
ation and IL2 gene expression (5), which we confirmed.
FK506 proved to be similar to CSA at the level of nuclear
transcription factors. The inductions ofNF-AT and AP-1 were
markedly reduced, whereas AP-3, NF-kB, OCT1, and the
factor that binds to the B site were not (Fig . 2) . We simul-
taneously evaluated extracts ofHeLa cell nuclei . These con-
tained all the nuclear factors that were inducible in T cells,
except for NF-AT, thus confirming thatNF-AT is atT cell-re-
stricted activity.
In additional experiments, CSA and FK506 blocked the
induction ofnuclear factors in response to the other mitogens,
anti-CD3 (not shown) or anti-CD28 mAb (Fig. 3) . Some
authors find that stimulation with anti-CD28 is CSA resis-
tant (15), but we noted that CSA reduced the induction of
IL2mRNA as well as nuclear factors that bind the IL-2 pro-
moter (16) (Fig. 3) .
We last tested dexamethasone, a glucocorticosteroid that
also inhibits the increase in IL2mRNA that occurs during
mitogenesis (6, 7) . While the drug clearly blocks the induc-
tion of IL-2 mRNA (not shown), dexamethasone did not
alter the induction of any of the factors that bind to the ele-
ments we have examined (Fig. 4) . These data indicate that
the 1172 transcriptional control pathway that is suppressed
by glucocorticoids is different from that ofCsA and FK506 .
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